|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
668402001
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1º´(2018.08.01)(ÇöÀç¾à°¡)
\2,796 ¿ø/1º´(2017.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öºÐ¸»ÀÇ ÁÖ»çÁ¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1, 5, 10, 50, 100¹ÙÀÌ¾Ë |
| ÁÖ¼ººÐÄÚµå |
328600BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
O À¯È¿±ÕÁ¾
*Ȳ»öÆ÷µµ±¸±Õ, *Ç¥ÇÇÆ÷µµ±¸±Õ, Æó·Å¿¬¼â±¸±Õ, ¿£Å×·ÎÄÛÄí½º ÆÄÀÌÄ®¸®½º, ½ºÆ®·¾ÅäÄÛÄí½º ÇÇ¿À°Ô³×½º(±×·ìA-º£Å¸¿ëÇ÷¼º), ½ºÆ®·¾ÅäÄÛÄí½º ºñ¸®´Ü½º, *ÀÎÇ÷翣ÀÚ±Õ, *ÆÄ¶óÀÎÇ÷翣ÀÚ±Õ, *¸ð¶ô¼¿¶ó īŸ¶ö¸®½º, *´ëÀå±Õ, *Ŭ·¹ºê½Ã¿¤¶ó, *ÇÁ·ÎÅ׿콺 ¹Ì¶óºô¸®½º, ÇÁ·ÎÅ׿콺 ºÒ°¡¸®½º, ÇÁ·Îºñµ§½Ã¾Æ ·¹Æ®°Ô¸®, ¸ð¸£°¡³Ú¶ó ¸ð¸£°¡´Ï, ¿£Å׷ιÚÅÍ, *ÀÓ±Õ, *¹ÚÅ×·ÎÀ̵å (¹ÚÅ×·ÎÀ̵ðÁî ÇÁ¶óÁú¸®½º Æ÷ÇÔ), ÇÁ·Îºñµ§½Ã¾Æ ½ºÅõ¾Æ¸£Æ¼
(* : º£Å¸¶ôŸ¸¶Á¦ »ý¼º±ÕÁÖ Æ÷ÇÔ)
O ÀûÀÀÁõ
- »ó ¡¤ ÇϺΠȣÈí±â°¨¿°Áõ (ÁßÀÌ¿°, Èĵΰ³¿°, ºÎºñµ¿¿° Æ÷ÇÔ)
- ¼¼±Õ¼ºÆó·Å
- ¿ä·Î°¨¿°Áõ ¹× ½Å¿ì½Å¿°
- º¹ºÎ³» °¨¿°Áõ (º¹¸·¿°, ´ã³¶¿°, Àڱ󻸷¿°, °ñ¹Ý¿¬Á¶Á÷¿° Æ÷ÇÔ)
- ÇǺΠ¹× ¿¬Á¶Á÷°¨¿°Áõ
- »À ¹× °üÀý°¨¿°Áõ
- ÀÓÁú
- º¹ºÎ ¹× ºÎÀΰú ¿Ü°ú ¼ö¼ú ÈÄ °¨¿°¹æÁö
|
| 1ÀÏ ÃÖ´ë Åõ¿©·® |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
* ÁÖ»ç¹æ¹ý
¤ý Á¤ÁÖ : Àû¾îµµ 10-15ºÐÀÌ»ó õõÈ÷ ÁÖ»ç, ÁÖÀÔ¾×À¸·Î¼ 50-100mL ÀÌ»óÀÇ Èñ¼®¾×À¸·Î 15-30ºÐÀÌ»ó ÁÖÀÔ.
¤ý ±ÙÀ°ÁÖ»ç ½Ã´Â ±í°Ô ÁÖ»çÇÑ´Ù.
1. ¼ºÀÎ : ¾ÏÇǽǸ°³ªÆ®·ý ¹× ¼³¹Ú޳ªÆ®·ýÀÇ È¥ÇÕ¹°·Î¼ 1ȸ 0.5-3g(¿ª°¡)À» 1ÀÏ 3-4ȸ Á¤¸ÆÁÖ»ç ¶Ç´Â ±ÙÀ°ÁÖ»ç ÇÑ´Ù. 1ÀÏ ÃÖ´ë¿ë·®Àº ¼³¹ÚŽÀ¸·Î¼ 4g(¿ª°¡)ÀÌ´Ù.
| °¨¿°ÁõÀÇ Á¤µµ |
1ÀÏ ¿ë·®(¾ÏÇǽǸ°³ªÆ®·ý¿ª°¡ + ¼³¹Ú޳ªÆ®·ý¿ª°¡) |
| °æÁõ |
1.5 ¢¦ 3g ( 1 + 0.5 ¢¦ 2 + 1 ) |
| ÁßµîÁõ |
¢¦ 6g ( 4 + 2 ) |
| ÁßÁõ |
¢¦ 12g ( 8 + 4 ) |
2. ½Å»ý¾Æ, À¯¾Æ, ¼Ò¾Æ : 1ÀÏ Kg´ç 60-150mg(¿ª°¡)À» 3-4ȸ ºÐÇÒÇÏ¿© Åõ¿©ÇÑ´Ù. ½Å»ý¾Æ ƯÈ÷ Á¶»ê¾ÆÀÇ °æ¿ì Ãâ»ý ÈÄ 1ÁÖ µ¿¾ÈÀº 2ȸ ºÐÇÒ(12½Ã°£ °£°ÝÀ¸·Î) Åõ¿©ÇÑ´Ù.
3. ½ÅÀå¾Ö ȯÀÚ(Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²ÀÌ 30mL/minÀÌÇÏ)´Â Åõ¿©È½¼ö¸¦ ÁÙ¿©¾ß ÇÑ´Ù.
4. ¿Ü°ú¼ö¼ú½Ã °¨¿°¿¹¹æÀÇ °æ¿ì ¸¶ÃëÀ¯µµÇÒ ¶§ 1.5-3g(¿ª°¡)À» Á¤¸ÆÁÖ»ç ¶Ç´Â ±ÙÀ°ÁÖ»çÇϸç ÇÊ¿äÇϸé 3-4ȸ ´õ Åõ¿©ÇÑ´Ù.
<ÀÌ ¾àÀÇ Á¶Á¦¹ý>
Á¤¸Æ ¶Ç´Â ±ÙÀ°ÁÖ»çÇϱâ À§ÇÏ¿© ÁÖ»ç¿ë Áõ·ù¼ö, ÁÖ»ç¿ë »ý¸®½Ä¿°¾× ¶Ç´Â Æ÷µµ´ç ÁÖ»ç¾×À¸·Î ¿ëÇØÇϸç Àû¾îµµ 3ºÐ ÀÌ»ó¿¡ °ÉÃÄ ÃµÃµÈ÷ ÁÖ»çÇÑ´Ù.
| |
¿ª°¡(g) |
|
ÃÖÁ¾³óµµ(mg/mL) |
| Ãѿ뷮(g) |
(¼³¹ÚŽ/¾ÏÇǽǸ°) |
Èñ¼®¾×ºÎÇÇ(mL) |
(¼³¹ÚŽ/¾ÏÇǽǸ°) |
| 0.75 |
(0.25/0.5) |
1.6 |
375(125/250) |
| 1.5 |
(0.5/1.0) |
3.2 |
375(125/250) |
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ ÀÇÇÏ¿© ¼ïÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ÀÌ ¾à ¼ººÐ ¶Ç´Â Æä´Ï½Ç¸°°è Ç×»ý¹°Áú¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
3) µ¿¹Ý°¨¿° ¹ÙÀÌ·¯½º Áúȯ ƯÈ÷ Àü¿°¼º´ÜÇÙ±¸Áõ ¹× ¸²ÇÁ¼º ¹éÇ÷º´ ȯÀÚ (¹ßÁøÀ§ÇèÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Ù.) |
| ½ÅÁßÅõ¿© |
1) ¼¼ÆÈ·Î½ºÆ÷¸°°è ¾à¹° ¹× ¿©·¯ °¡Áö ¾Ë·¹¸£±â À¯¹ß Ç׿ø¿¡ °ú¹Î¹ÝÀÀÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±âÁõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀ» °¡Áø ȯÀÚ
3) ÁßÁõ ½ÅÀå¾Ö ȯÀÚ
4) °æ±¸¼·Ãë°¡ ºÒ·®ÇÑ È¯ÀÚ ¶Ç´Â ºñ°æ±¸¿µ¾çȯÀÚ, °í·ÉÀÚ, Àü½Å»óŰ¡ ³ª»Û ȯÀÚ (ºñŸ¹Î K °áÇÌ¿¡ ÀÇÇÑ ÃâÇ÷°æÇâÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÃæºÐÈ÷ °üÂûÇÑ´Ù.)
5) 1¼¼ ¹Ì¸¸ÀÇ ¿µ¾Æ |
| ÀÌ»ó¹ÝÀÀ |
1) ¾ÏÇǽǸ° ´Üµ¶ Åõ¿©¿Í °ü·Ã¼º ÀÖ´Â ¾à¹°ÀÌ»ó¹ÝÀÀµµ ÀÌ ¾àÀÇ Åõ¿©·Î ÀÎÇØ °üÂûµÉ ¼ö ÀÖ´Ù. ¾Æ·¡¿¡ ±âÀçµÈ ¸ðµç ¾à¹°ÀÌ»ó¹ÝÀÀµéÀº MedDRA SOC·Î Ç¥½ÃµÇ¾îÀÖ´Ù. ºóµµ´Â ´ÙÀ½°ú °°ÀÌ ºÐ·ùµÈ´Ù: ¸Å¿ì ÈçÇÏ°Ô ¡Ã1/10, (¡Ã10%), ÈçÇÏ°Ô ¡Ã1/100, <1/10 (¡Ã1% ¹× <10%); ÈçÇÏÁö ¾Ê°Ô: ¡Ã1/1000, <1/100 (¡Ã0.1% ¹× <1%); µå¹°°Ô: ¡Ã1/10,000, < 1/1000 (¡Ã0.01% ¹× <0.1%); ºóµµºÒ¸í: ºóµµ´Â ¾Ë·ÁÁø ÀÚ·á·Î Æò°¡ÇÒ ¼ö ¾øÀ½.
| ±â°ü°è ºÐ·ù |
¸Å¿ì ÈçÇÏ°Ô |
ÈçÇÏ°Ô |
ÈçÇÏÁö ¾Ê°Ô |
µå¹°°Ô |
ºóµµ ºÒ¸í |
| Ç÷¾× ¹× ¸²ÇÁ°è |
|
ºóÇ÷, Ç÷¼ÒÆÇ°¨¼Ò, È£»ê±¸Áõ°¡, ÀûÇ÷±¸°¨¼Ò, ¸²ÇÁ±¸Áõ°¡, ´ÜÇÙ±¸Áõ°¡ |
¹éÇ÷±¸ °¨¼ÒÁõ, Áß¼º±¸ °¨¼ÒÁõ, È£¿°±¸Áõ°¡ |
ÃâÇ÷ °æÇâ |
¿ëÇ÷¼ººóÇ÷, ¹«°ú¸³±¸Áõ, Ç÷¼ÒÆÇ°¨¼ÒÀÚ»ö¹Ý, Ç÷¼ÒÆÇ Áõ°¡, ºñŸ¹Î K °áÇÌÁõ»ó (ÀúÇÁ·ÎÆ®·ÒºóÇ÷Áõ) |
| ¸é¿ª°è |
|
|
|
|
¾Æ³ªÇʶô½Ã½º¼îÅ©, ¾Æ³ªÇʶô½Ã½º¹ÝÀÀ, À¯»ç¾Æ³ªÇʶô½Ã½º¼îÅ©, À¯»ç¾Æ³ªÇʶô½Ã½º¹ÝÀÀ, °ú¹ÎÁõ |
| ½Å°æ°è |
|
|
µÎÅë |
|
°æ·Ã, ¾îÁö·¯¿ò, Á¹¸², ÁøÁ¤, ÀϽÃÀû ¹Ì°¢º¯È |
| Ç÷°ü |
|
Á¤¸Æ¿° (Ç÷Àü¼ºÁ¤¸Æ¿°Æ÷ÇÔ) |
|
|
|
| À§Àå°ü |
|
¼³»ç* |
±¸Åä* |
±¸¿ª*, ¼³¿°*, À§ºÎºÒÄè°¨*, °íâ*, º¹ºÎÆØ¸¸* |
À§¸·¼º´ëÀå¿°*, ¼ÒÀå°áÀå¿°*, º¹Åë, Èæ»öº¯, ¼ÒȺҷ®, ±¸³»¿°, Çôº¯»ö, ¹±Àºº¯*, À§¿°*, Èæ¸ð¼³*,, ±¸°°ÇÁ¶°¨ |
| °£´ãµµ |
|
°íºô¸®·çºóÇ÷Áõ |
|
|
´ãÁóÁ¤Ã¼¼º°£¿°, ´ãÁóÁ¤Ã¼, °£±â´É ÀÌ»ó, Ȳ´Þ |
| ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ |
|
|
¹ßÁø, °¡·Á¿ò |
|
½ºÆ¼ºì½º-Á¸½¼ ÁõÈıº, µ¶¼ºÇ¥ÇDZ«»ç¿ëÇØ, ´ÙÇüÈ«¹Ý, ±Þ¼º Àü½Å ¹ßÁø ³óÆ÷Áõ, ¹ÚÅ»ÇǺο°, Ç÷°üºÎÁ¾, µÎµå·¯±â, ÇǺο° |
| ½ÅÀå ¹× ºñ´¢±â°è |
|
|
BUN»ó½Â, Å©·¹¾ÆÆ¼´ÑÄ¡ »ó½Â |
´¢Á¤Ã¼, ¹è´¢°ï¶õ |
¼¼´¢°ü°£Áú¼º½Å¿°, ±Þ¼º ½ÅºÎÀü, ´¢¿¡¼ ÀûÇ÷±¸ ¹× È÷¾Ë¸°°áÁ¤ »ý¼º |
| Àü½Å ¹× Åõ¿© ºÎÀ§ ¹ÝÀÀ |
|
ÁÖ»çºÎÀ§ ÅëÁõ |
ÇÇ·Î, ±ÇÅÂ, ÈäÅë, ºÎÁ¾ |
¿ÀÇÑ, ¾È¸éºÎÁ¾ |
ÁÖ»çºÎÀ§ ¹ÝÀÀ, ºñŸ¹Î B±º °áÇÌÁõ»ó(½Ä¿åºÎÁø, ½Å°æ¿° µî), ¹ß¿ |
| È£Èí±â°è |
|
|
|
ÄÚÇÇ |
È£Èí°ï¶õ |
| °¨¿° |
|
|
Áø±Õ°¨¿° |
|
±Õ±³´ëÁõ (±¸³»¿°, ĵð´ÙÁõ) |
| ½ÇÇè½Ç °Ë»ç |
Á¥»êÅ»¼ö¼ÒÈ¿¼Ò(LDH)»ó½Â |
¾Ë¶ó´Ñ ¾Æ¹Ì³ë ÀüÀÌÈ¿¼Ò(ALT) »ó½Â, ¾Æ½ºÆÄ¸£Å×ÀÌÆ® ¾Æ¹Ì³ëÀüÀÌÈ¿¼Ò(AST) »ó½Â, Ç÷û ¾ËºÎ¹Î °¨¼Ò, Ç÷û ÃÑ ´Ü¹éÁú °¨¼Ò, ¾ËÄ®¸®ÀλêºÐÇØÈ¿¼Ò(ALP)»ó½Â |
|
|
Ç÷¼ÒÆÇÀÀÁý ÀÌ»ó |
| *ÀÌ·¯ÇÑ Áõ»óµéÀº ƯÈ÷ ³¶Æ÷¼º¼¶À¯Áõ¿¡ °É¸° ¼Ò¾Æµé¿¡°Ô¼ ºó¹øÇÏ°Ô ¹ß»ýÇÑ´Ù (Àüü »ç·Ê Áß 80%). |
|
| »óÈ£ÀÛ¿ë |
1) ¾Ë·ÎǪ¸®³î: ¾Ë·ÎǪ¸®³î°ú ¾ÏÇǽǸ°À» º´¿ë Åõ¿©ÇÏ´Â °æ¿ì ¾ÏÇǽǸ°¸¸À» ´Üµ¶À¸·Î Åõ¿©ÇÏ´Â °æ¿ì¿¡ ºñÇØ ¹ßÁøÀÌ ³ªÅ¸³ª´Â ºñÀ²ÀÌ ÈξÀ ³ô°Ô ³ªÅ¸³µ´Ù.
2) Ç×ÀÀ°íÁ¦: ºñ°æ±¸ Æä´Ï½Ç¸°°è ¾à¹°À» Åõ¿©ÇÏ´Â °æ¿ì Ç÷¼ÒÆÇ ÀÀÁý°ú Ç÷¾×ÀÀ°í °Ë»ç¿¡¼ ÀÌ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ ÀÛ¿ëÀº Ç×ÀÀ°íÁ¦¿Í º´¿ëÇÏ´Â °æ¿ì ±× °á°ú°¡ »ó°¡ÀûÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) Á¤±ÕÁ¦ (Ŭ·Î¶÷Æä´ÏÄÝ, ¿¡¸®½º·Î¸¶À̽Å, ¼³Æù¾Æ¸¶À̵å°è ¾à¹° ¹× Åׯ®¶ó»çÀÌŬ¸°°è ¾à¹°): Á¤±ÕÁ¦´Â Æä´Ï½Ç¸°ÀÇ »ì±ÕÀÛ¿ëÀ» ¹æÇØÇÒ ¼ö ÀÖÀ¸¹Ç·Î, º´¿ëÅõ¿©¸¦ ÇÇÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù.
4) ¿¡½ºÆ®·ÎÁ¨ ÇÔÀ¯ °æ±¸¿ë ÇÇÀÓÁ¦: ¾ÏÇǽǸ°À» º¹¿ë ÁßÀÎ ¿©¼º¿¡°Ô¼ °æ±¸¿ë ÇÇÀÓÁ¦ÀÇ ÇÇÀÓÈ¿°ú°¡ °¨¼ÒµÇ¾î °èȹÇÏÁö ¾ÊÀº ÀÓ½ÅÀ» ÇÏ°Ô µÈ ¿¹°¡ º¸°íµÇ¾î ÀÖ´Ù. ±× »ó°ü°ü°è´Â ¹Ì¾àÇÏÁö¸¸, ¾ÏÇǽǸ°À» º¹¿ëÇÏ´Â µ¿¾È ´Ù¸¥ ÇÇÀÓ¹ýÀ¸·Î ¹Ù²Ù°Å³ª ȤÀº ´Ù¸¥ ÇÇÀÓ¹ýÀ» Ãß°¡·Î ÇÔ²² »ç¿ëÇÒ °ÍÀ» ȯÀÚ¿¡°Ô ¾Ë·Á¾ß ÇÑ´Ù.
5) ¸ÞÅ䯮·º¼¼ÀÌÆ®: Æä´Ï½Ç¸°°è ¾à¹°°úÀÇ º´¿ëÅõ¿©·Î ÀÎÇØ ¸ÞÅ䯮·º¼¼ÀÌÆ®ÀÇ Ã»¼ÒÀ²ÀÌ °¨¼ÒµÇ°í ¸ÞÅ䯮·º¼¼ÀÌÆ®¿¡ ÀÇÇÑ µ¶¼ºÀÌ Áõ°¡µÈ´Ù. ȯÀÚ¸¦ ¸é¹ÐÈ÷ ¸ð´ÏÅ͸µÇÏ¿©¾ß ÇÑ´Ù. ·ùÄÚº¸¸°ÀÇ ¿ë·®À» Áõ·®Çϰųª Åõ¿©±â°£À» ¿¬Àå½ÃÄÑ¾ß ÇÒ Çʿ䰡 ÀÖÀ» ¼öµµ ÀÖ´Ù.
6) ÇÁ·Îº£³×½Ãµå: ÇÁ·Îº£³×½Ãµå´Â ¾ÏÇǽǸ° ¹× ¼³¹Úްú º´¿ëÅõ¿© ½Ã ÀÌµé ¾à¹°ÀÇ ½Å¼¼´¢°ü ºÐºñ¸¦ °¨¼Ò½ÃŲ´Ù. ±× °á°ú ÀÌµé ¾à¹°ÀÇ Ç÷Áß ³óµµ°¡ Áõ°¡µÇ°í ±× ±â°£ ¶ÇÇÑ ¿¬ÀåµÇ¸ç, ¾à¹°Á¦°Å ¹Ý°¨±â°¡ ±æ¾îÁö°í, µ¶¼ºÀÇ À§Ç輺ÀÌ Áõ°¡µÈ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ampicillin¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Ampicillin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Ampicillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Ampicillin interferes with an autolysin inhibitor.
|
| Pharmacology |
Ampicillin¿¡ ´ëÇÑ Pharmacology Á¤º¸ Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Ampicillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ampicillin results from the inhibition of cell wall synthesis and is mediated through Ampicillin binding to penicillin binding proteins (PBPs). Ampicillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
|
| Metabolism |
Ampicillin¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Ampicillin¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Ampicillin¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Ampicillin¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Ampicillin sodiumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- »ýü³»ÀÌ¿ë·ü : °æ±¸ : 50%
- ºÐÆ÷ : ´ãÁ󳻿¡ ºÐÆ÷, ¿°Áõ¼º ³ú¸·¿¡¼¸¸ ³úô¼ö¾×À¸·Î Àß Åõ°úµÈ´Ù (ÀϹÝÀûÀ¸·Î MICs ÀÌ»ó).
- ³úô¼ö¾× ´ë Ç÷¾×ÀÇ ³óµµºñ(%)
- Á¤»ó ³ú¸· : 0
- ¿°Áõ¼º ³ú¸· : 5-10
- ´Ü¹é°áÇÕ : 15-25%
- ¹Ý°¨±â :
- ½Å»ý¾Æ :
2-7ÀÏ : 4½Ã°£
8-14ÀÏ : 2.8½Ã°£
15-30ÀÏ : 1.7½Ã°£
- ¼Ò¾Æ ¹× ¼ºÀÎ : 1-1.8 ½Ã°£
- ¹«´¢Áõ/¸»±â ½ÅÁúȯ : 7-20 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1-2 ½Ã°£ À̳»
- ¼Ò½Ç : 24½Ã°£ À̳»¿¡ 90%±îÁö ¹Ìº¯Èü·Î ½Å¹è¼³µÈ´Ù.
Sulbactam SodiumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ºÐÆ÷ :
- ´ãÁó, ¼öÆ÷, Á¶Á÷¾×¿¡ ºÐÆ÷
- ºñ¿°Áõ¼º ³ú¸· : ³úô¼ö¾×À¸·Î °ÅÀÇ Åõ°úµÇÁö ¾Ê´Â´Ù.
- ¿°Áõ¼º ³ú¸· : ºñ¿°Áõ¼º ³ú¸·º¸´Ù´Â ´õ ³ôÀº ³óµµ·Î ºÐÆ÷
- ´Ü¹é°áÇÕ :
- Ampicillin : 28%
- Sulbactam : 38%
- ¹Ý°¨±â : Ampicillin, sulbactam : µÎ ¾à¹°ÀÇ ¹Ý°¨±â´Â À¯»çÇÏ´Ù.
- Á¤»ó ½Å±â´ÉÀÎ °æ¿ì :
- Ampicillin : 1-1.8 ½Ã°£
- Sulbactam : 1-1.3 ½Ã°£
- ¼Ò½Ç : Åõ¿©ÇÑ Áö 8½Ã°£ À̳»¿¡ µÎ ¾à¹° ¸ðµÎ 75-85%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³µÈ´Ù.
|
| Biotransformation |
Ampicillin¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Ampicillin¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Ampicillin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Methotrexate The penicillin increases the effect and toxicity of methotrexateAnisindione The IV penicillin increases the anticoagulant effectAtenolol Ampicillin decreases bioavailability of atenololDemeclocycline Possible antagonism of actionDicumarol The IV penicillin increases the anticoagulant effectDoxycycline Possible antagonism of actionEthinyl Estradiol This anti-infectious agent could decrease the effect of the oral contraceptiveMethacycline Possible antagonism of actionMinocycline Possible antagonism of actionAcenocoumarol The IV penicillin increases the anticoagulant effectOxytetracycline Possible antagonism of actionRolitetracycline Possible antagonism of actionTetracycline Possible antagonism of actionWarfarin The IV penicillin increases the anticoagulant effectMestranol This anti-infectious agent could decrease the effect of the oral contraceptive
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Ampicillin¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take on an empty stomach.
|
| Drug Target |
[Drug Target]
|
| Description |
Ampicillin¿¡ ´ëÇÑ Description Á¤º¸ Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. [PubChem]
|
| Drug Category |
Ampicillin¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Bacterial AgentsPenicillins
|
| Smiles String Canonical |
Ampicillin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1(C)SC2C(NC(=O)C(N)C3=CC=CC=C3)C(=O)N2C1C(O)=O
|
| Smiles String Isomeric |
Ampicillin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O
|
| InChI Identifier |
Ampicillin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1/f/h18,22H
|
| Chemical IUPAC Name |
Ampicillin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-08-19
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|